SPARC is the Bollywood struggler of pharma – good family background (Sun Pharma), big dreams (Alzheimer’s, cancer, alopecia cures), but still waiting for its first real “box office hit.” In Q1 FY26, revenue limped at ₹9.6 Cr (–43% YoY), while losses deepened to ₹52 Cr. OPM? A hilarious –543%, because SPARC spends five rupees to earn one.
2. Introduction
Imagine running an R&D company where expenses are infinite, revenues are license scraps, and shareholders are basically funding a decade-long clinical trial. Welcome to SPARC.
This is the first listed Indian pharma R&D company, spun off from Sun Pharma to chase “high science.” The Shanghvi family (promoters still own 65%) keep pumping money, warrant conversions, and guarantees – like a father bailing out his startup son who insists, “Bas ek aur year, then unicorn ban jaayega.”
Pipeline includes exotic compounds with names scarier than exam hall roll calls: Vodobatinib (neurodegenerative diseases), SCD-153 (alopecia), Vibozilimod (autoimmune), and SBO-154 (oncology ADC). Investors wait, trials drag, money burns.
Question: Are you patient enough to fund 10 years of red ink for the chance of one blockbuster drug?
3. Business Model – WTF Do They Even Do?
SPARC doesn’t sell pills. It sells hope.
Revenue = Licensing fees + royalties + R&D services. Think of it as “pocket money” from out-licensing molecules.
Core business = Drug discovery & delivery innovation. Fancy terms: NCE (new chemical entity), NDDS (new drug delivery systems). Earlier, 80% of work was NDDS; now focus has shifted to NCEs (62% of pipeline). Translation: They went from “making old drugs easier to swallow” to “let’s invent new drugs nobody has.”
Product portfolio – still clinical-stage. The only approved baby: Sezaby (phenobarbital sodium injection) licensed to a partner. Rest are stuck in expensive global trials.
It’s a lottery model: 90% chances of failure, 10% chance of jackpot.
